NCT03702582View on ClinicalTrials.gov

Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

October 1, 2023

Study Completion Date

October 1, 2023

Conditions
Atrial FibrillationStrokeBleeding
Interventions
DRUG

Rivaroxaban

Anticoagulant drug that works via direct inhibition of factor Xa. FDA approved for prophylaxis against stroke in non-valvular atrial fibrillation

DRUG

Warfarin

Anticoagulation drug that works via inhibition of vitamin K dependent clotting factors. FDA approved for prophylaxis against stroke in atrial fibrillation

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT03702582 - Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation | Biotech Hunter | Biotech Hunter